We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Trimble
TRMB
$13.5B
| $1.96M | 0.01% |
25,809
+5,043
| +24% | +$339K |
|
727
Praxis Precision Medicines
PRAX
$8.58B
| $1.93M | 0.01% |
45,952
-129,775
| -74% | -$4.94M |
|
728
First Solar
FSLR
$25.4B
| $1.92M | 0.01% |
11,600
+2,556
| +28% | +$377K |
|
729
Halliburton
HAL
$26.4B
| $1.9M | 0.01% |
92,995
+19,654
| +27% | +$412K |
|
730
Evolus
EOLS
$403M
| $1.88M | 0.01% |
+204,562
| New | +$2.09M |
|
731
Editas Medicine
EDIT
$416M
| $1.86M | 0.01% |
+846,399
| New | +$1.38M |
|
732
KeyCorp
KEY
$24.5B
| $1.86M | 0.01% |
106,684
+22,528
| +27% | +$349K |
|
733
Cabaletta Bio
CABA
$445M
| $1.85M | 0.01% |
+1,218,464
| New | +$1.9M |
|
|
OMDA
734
Omada Health Inc
OMDA
$1.22B
| $1.83M | 0.01% |
+100,000
| New | +$1.73M |
|
735
Genuine Parts
GPC
$17.7B
| $1.82M | 0.01% |
15,013
+3,267
| +28% | +$393K |
|
|
BBNX
736
Beta Bionics
BBNX
$609M
| $1.82M | 0.01% |
125,000
| – | – |
|
737
Larimar Therapeutics
LRMR
$403M
| $1.8M | 0.01% |
622,682
| – | – |
|
738
Phathom Pharmaceuticals
PHAT
$727M
| $1.8M | 0.01% |
187,291
-564,401
| -75% | -$3.12M |
|
739
Zebra Technologies
ZBRA
$17.1B
| $1.79M | 0.01% |
5,803
-16,987
| -75% | -$4.61M |
|
740
Snap-on
SNA
$21.3B
| $1.76M | 0.01% |
5,656
+1,230
| +28% | +$391K |
|
741
3M
MMM
$91.7B
| $1.75M | 0.01% |
+11,518
| New | +$1.65M |
|
742
Loews
L
$23.7B
| $1.73M | 0.01% |
18,827
+3,901
| +26% | +$342K |
|
743
Akamai
AKAM
$17.3B
| $1.72M | 0.01% |
21,568
-164,468
| -88% | -$12.8M |
|
744
Evergy
EVRG
$19B
| $1.72M | 0.01% |
24,889
+5,460
| +28% | +$367K |
|
745
Rollins
ROL
$18.2B
| $1.72M | 0.01% |
30,407
+6,679
| +28% | +$375K |
|
746
Occidental Petroleum
OXY
$54B
| $1.71M | 0.01% |
40,747
-16,332
| -29% | -$683K |
|
747
Jacobs Solutions
J
$16.4B
| $1.71M | 0.01% |
12,997
+2,540
| +24% | +$313K |
|
748
Automatic Data Processing
ADP
$106B
| $1.7M | 0.01% |
5,509
+128
| +2% | +$39.3K |
|
749
Expeditors International
EXPD
$22.3B
| $1.69M | 0.01% |
14,813
+2,987
| +25% | +$334K |
|
750
Alliant Energy
LNT
$18.3B
| $1.68M | 0.01% |
27,785
+6,106
| +28% | +$374K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.